3,006 Shares in Thermo Fisher Scientific Inc. $TMO Bought by First Nebraska Trust Co

First Nebraska Trust Co acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,006 shares of the medical research company’s stock, valued at approximately $2,029,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Thermo Fisher Scientific in the second quarter valued at $15,501,867,000. Corient Private Wealth LP purchased a new position in shares of Thermo Fisher Scientific in the second quarter valued at $382,547,000. Bank of New York Mellon Corp acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $1,974,561,000. Bank of America Corp DE acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Thermo Fisher Scientific by 0.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock worth $1,239,625,000 after buying an additional 22,827 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 2.3%

TMO stock opened at $698.24 on Wednesday. The company has a 50 day moving average price of $657.33 and a two-hundred day moving average price of $553.71. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a market capitalization of $258.71 billion, a P/E ratio of 36.83, a PEG ratio of 2.78 and a beta of 0.84. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $711.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The company had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same quarter in the prior year, the company posted $5.79 EPS. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This trade represents a 12.40% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 76,199 shares of company stock valued at $45,896,780. 0.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TMO. Guggenheim began coverage on shares of Thermo Fisher Scientific in a research note on Thursday, October 15th. They issued a “buy” rating on the stock. TD Cowen lifted their target price on shares of Thermo Fisher Scientific from $760.00 to $810.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Wells Fargo & Company downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a report on Wednesday, September 9th. DZ Bank lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. Finally, CLSA began coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $689.10.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.